Associated Papers
Unveiling splicing disruptions due to common somatic variants in acute myeloid leukemia.
Morote-Faubel M et al.
Human Genomics, 2025
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
A comprehensive benchmark for multiple highly efficient base editors with broad targeting scope.
Wang X et al.
Biorxiv : the Preprint Server for Biology, 2025
Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.
Gordon J et al.
Blood Cancer Journal, 2024
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H et al.
Blood Advances, 2024
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
A new genomic framework to categorize pediatric acute myeloid leukemia.
Umeda M et al.
Nature Genetics, 2024
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
Ge SS et al.
British Journal of Haematology, 2023
Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).
Rehn J et al.
Plos Genetics, 2022
Cancer-driving mutations are enriched in genic regions intolerant to germline variation.
Vitsios D et al.
Science Advances, 2022
Genetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Kang D et al.
Journal of Clinical Medicine, 2022
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Wagner AJ et al.
Jama Oncology, 2021
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H et al.
Annals of Hematology, 2020
KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM et al.
Yonsei Medical Journal, 2020
Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
He R et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.
Wu Y et al.
Journal of Medicinal Chemistry, 2019
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Zhang H et al.
Nature Communications, 2019
appreci8: a pipeline for precise variant calling integrating 8 tools.
Sandmann S et al.
Bioinformatics (oxford, England), 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M et al.
Leukemia, 2018
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Madan V et al.
Leukemia, 2016
Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.
Ke H et al.
Cell & Bioscience, 2016
Stem cell factor receptor/c-Kit: from basic science to clinical implications.
Lennartsson J et al.
Physiological Reviews, 2012
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2012
[c-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs)].
He HY et al.
Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences, 2005